$0.9854
0.0088[0.90%]
At close: May 14
$0.9854
0[0.00%]
After Hours: 4:00PM EDT
X4 Pharmaceuticals
(NASDAQ:XFOR)Latest News for X4 Pharmaceuticals Stock (NASDAQ:XFOR)
X4 Pharmaceuticals Stock (NASDAQ: XFOR)
Categories: All
Tuesday, May 07, 2024
Tuesday, April 30, 2024
Monday, April 29, 2024
- FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency DisorderVandana Singh - Apr 29, 2024, 12:10PM
- X4 Pharmaceuticals shares are trading higher after the FDA approved the company's Xolremdi (mavorixafor) for WHIM syndrome.Benzinga Newsdesk - Apr 29, 2024, 6:34AM
- FDA Approves X4 Pharmaceuticals' Xolremdi (Mavorixafor) Capsules For Use In Patients 12 Years Of Age And Older With WHIM Syndrome To Increase The Number Of Circulating Mature Neutrophils And LymphocytesBenzinga Newsdesk - Apr 29, 2024, 6:32AM
Friday, April 26, 2024
Friday, March 22, 2024
Thursday, March 21, 2024
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Mar 21, 2024, 1:31PM
- X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS results.Benzinga Newsdesk - Mar 21, 2024, 12:08PM
- Earnings Scheduled For March 21, 2024Benzinga Insights - Mar 21, 2024, 6:15AM
- Recap: X4 Pharmaceuticals Q4 EarningsBenzinga Insights - Mar 21, 2024, 6:15AM
- X4 Pharmaceuticals Q4 EPS $(0.10) Beats $(0.15) EstimateBenzinga Newsdesk - Mar 21, 2024, 6:02AM
Wednesday, March 20, 2024
Tuesday, December 12, 2023
Monday, December 11, 2023
- Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Dec 11, 2023, 1:12PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Dec 11, 2023, 12:30PM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Dec 11, 2023, 8:06AM
- Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Dec 11, 2023, 7:59AM
- Saturday, X4 Pharmaceuticals Announced Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023Benzinga Newsdesk - Dec 11, 2023, 6:58AM
Thursday, November 09, 2023
Wednesday, November 08, 2023
Tuesday, October 31, 2023
- X4 Pharmaceuticals shares are trading higher after the company announced FDA acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM syndrome.Benzinga Newsdesk - Oct 31, 2023, 2:23PM
- X4 Pharmaceuticals Announces FDA Acceptance With Priority Review Of US NDA For Mavorixafor In WHIM SyndromeBenzinga Newsdesk - Oct 31, 2023, 8:03AM
Tuesday, August 15, 2023
Friday, August 11, 2023
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Aug 11, 2023, 1:31PM
- Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About YetChris Katje - Aug 11, 2023, 10:54AM
- HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price TargetBenzinga Newsdesk - Aug 11, 2023, 7:25AM
Thursday, August 10, 2023
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Aug 10, 2023, 1:31PM
- Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Aug 10, 2023, 1:17PM
- X4 Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results.Benzinga Newsdesk - Aug 10, 2023, 11:52AM
- Earnings Scheduled For August 10, 2023Benzinga Insights - Aug 10, 2023, 6:59AM
- X4 Had $142.3M Expected To Be Sufficient Funds To Support Company Operations Into 2025Benzinga Newsdesk - Aug 10, 2023, 6:09AM
- X4 Pharmaceuticals Q2 EPS $(0.33) Misses $(0.16) EstimateBenzinga Newsdesk - Aug 10, 2023, 6:05AM
Wednesday, June 14, 2023
Tuesday, June 13, 2023
Wednesday, May 17, 2023
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - May 17, 2023, 1:31PM
- X4 Pharmaceuticals shares are trading higher after the company announced Phase 3 results showing mavorixafor reduced the rate, severity, and duration of infections vs. placebo in participants diagnosed with WHIM syndrome.Benzinga Newsdesk - May 17, 2023, 10:39AM
- Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5Benzinga Newsdesk - May 17, 2023, 10:24AM
- X4 Pharma Highlights 'Significant Reduction' Rate In Severity, Duration Of InfectionsVandana Singh - May 17, 2023, 9:45AM
Tuesday, May 16, 2023
- X4 Pharmaceuticals Announces Phase 3 Results Showing Mavorixafor Reduced The Rate, Severity, And Duration Of Infections vs. Placebo In Participants Diagnosed With WHIM SyndromeHappy Mohamed - May 16, 2023, 4:09PM
- X4 Pharmaceuticals shares are trading higher after the company announced a $65 million private placement of about 42 million shares of common stock priced at-the-market.Benzinga Newsdesk - May 16, 2023, 11:44AM
- X4 Pharmaceuticals Announces $65M Private Placement Of 42,784,203 Shares Of Common Stock Priced At-The-MarketBenzinga Newsdesk - May 16, 2023, 8:35AM